Company: PFSA
Filing Date: 2025-10-29
Form Type: 424B3
Source: 0001213900-25-103174
Chunk: 25

Company: Profusa, Inc.
Filing Date: 2025-10-29
Form: 424B3
Chunk 25
---
 reviewing bodies may not authorize us or our investigators to commence a clinical trial, or to conduct 
 or continue a clinical trial at a prospective or specific trial site;                                                                   |

| ● | we may not reach agreement on acceptable terms with prospective contract research organizations, or CROs,                                
 and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and 
 trial sites;                                                                                                                             |

| ● | clinical trials may produce negative or inconclusive results, and we may decide, or regulators may require 
 us, to conduct additional clinical trials or abandon product development programs;                         |

| ● | the number of subjects required for clinical trials may be larger than we anticipate, enrollment in these                             
 clinical trials may be insufficient or slower than we anticipate, and the number of clinical trials being conducted at any given time 
 may be high and result in fewer available subjects for any given clinical trial, or subjects may drop out of these clinical trials at 
 a higher rate than we anticipate;                                                                                                     |

| ● | our third-party contractors, including those manufacturing products or conducting clinical trials or preclinical                       
 studies on our behalf, may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, 
 or at all;                                                                                                                             |

| ● | we might have to suspend or terminate clinical trials for various reasons, including a finding that the 
 subjects are being exposed to unacceptable health risks;                                                |

| ● | we may have to amend clinical trial protocols or conduct additional studies to reflect changes in regulatory             
 requirements or guidance, which we may be required to submit to an IRB and/or regulatory authorities for re-examination; |

| ● | regulators, IRBs or other parties may require or recommend that we or our investigators suspend or terminate   
 clinical research for various reasons, including safety signals or noncompliance with regulatory requirements; |

| ● | the cost of clinical trials may be greater than we anticipate; |

| ● | clinical sites may not adhere to the clinical protocol or may drop out of a clinical trial; |

<div align='center'>12</div>

| ● | we may be unable to recruit a sufficient number of clinical trial sites or study participants; |

| ● | regulators, IRBs or other reviewing bodies may find fault with our manufacturing processes or facilities                                        
 of third-party manufacturers with which we enter into agreement for clinical and commercial supplies, the supply of devices or other materials  
 necessary to conduct clinical trials may be insufficient, inadequate or not available at an acceptable cost,